These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8646723)

  • 1. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma.
    Di Leo A; Bajetta E; Ferrari L; Biganzoli L; Mariani L; Carnaghi C; Camerini E; Buzzoni R; Ruiz JM
    Cancer; 1996 Jul; 78(1):35-42. PubMed ID: 8646723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
    Chanson P; Leselbaum A; Blumberg J; Schaison G
    Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications.
    Caron P; Tabarin A; Cogne M; Chanson P; Jaquet P
    Eur J Endocrinol; 2000 Jun; 142(6):565-71. PubMed ID: 10822218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
    Lucas T; Astorga R; Catalá M;
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of delayed-release lanreotide in the medical therapy of acromegaly].
    Papi G; Magnoni I; Pesenti M; Gola M; Tavernari V; Velardo A
    Minerva Endocrinol; 1998 Jun; 23(2):57-63. PubMed ID: 9844356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
    Colao A; Marzullo P; Ferone D; Marinò V; Pivonello R; Di Somma C; Di Sarno A; Giaccio A; Lombardi G
    J Endocrinol Invest; 1999 Jan; 22(1):40-7. PubMed ID: 10090136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology.
    Di Leo A; Ferrari L; Bajetta E; Bartoli C; Vicario G; Moglia D; Miceli R; Callegari M; Bono A
    Breast Cancer Res Treat; 1995 Jun; 34(3):237-44. PubMed ID: 7579488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1.
    Garrido MJ; Cendrós JM; Ramis J; Peraire C; Obach R; Trocóniz IF
    J Clin Pharmacol; 2012 Apr; 52(4):487-98. PubMed ID: 21551318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
    Tomassetti P; Migliori M; Gullo L
    Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days.
    Bronstein M; Musolino N; Jallad R; Cendros JM; Ramis J; Obach R; Leselbaum A; Catus F
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):514-9. PubMed ID: 16268802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension.
    Melmed S; Cook D; Schopohl J; Goth MI; Lam KS; Marek J
    Pituitary; 2010; 13(1):18-28. PubMed ID: 19639415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.
    Wymenga AN; Eriksson B; Salmela PI; Jacobsen MB; Van Cutsem EJ; Fiasse RH; Välimäki MJ; Renstrup J; de Vries EG; Oberg KE
    J Clin Oncol; 1999 Apr; 17(4):1111. PubMed ID: 10561168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.